India seizes suspected counterfeit Mounjaro pens sourced through online marketplaces

Drug regulators in India's Haryana state seized more than 260 suspected counterfeit pens of Mounjaro, Eli Lilly's diabetes and weight-loss drug, and arrested two people accused of manufacturing and selling them, according to the Haryana Food and Drug Control Administration ^[1]. Officials say the main suspect had no pharmaceutical license and made the products at a private property outside New Delhi ^[1].

Investigators told Reuters the peptides used to make the fake pens were sourced from vendors on Alibaba, the Chinese e-commerce platform, and that officials recovered large quantities of raw materials, including locally made Mounjaro packaging labels, from the property ^[1]. The recovered materials were valued at roughly 7 million rupees, and the pens themselves were sold through the online marketplace IndiaMART at a 27% discount to the price of the genuine drug, a drug control officer said ^[1]. Reuters said it could not independently verify these claims, and Alibaba and IndiaMART did not immediately respond to requests for comment ^[1].

Officials said the seized pens were not stored under proper temperature conditions and had differences in font sizes and other label details compared with the authentic product, which raised suspicion that they were counterfeit ^[1]. Samples have been sent to government laboratories for confirmation, and the two arrested individuals are in judicial remand while the investigation continues ^[1].

Mounjaro launched in India in 2025 and has become the country's top-selling drug by value ^[1]. India's broader obesity drug market, which includes Mounjaro along with Novo Nordisk's weight-loss products and newer generic alternatives, is projected to reach 80 billion rupees, or about $859 million, by 2030 ^[1]. Lilly said in a statement that it "takes patient safety extremely seriously and welcomes regulatory authority's action against illicit medicines," adding that it is supporting the investigation ^[1].

Why it matters for patients

This case took place in India, not the United States, but it shows how quickly counterfeit supply chains can form around a drug that is in high demand and short supply. Genuine GLP-1 medications like Mounjaro require precise manufacturing and cold-chain storage to remain safe and effective. The seized pens in this case were reportedly not kept at proper temperatures, and officials flagged visible differences in labeling compared with authentic packaging ^[1]. Counterfeit products bought outside licensed pharmacies carry unknown risks because their contents, purity, and dosing cannot be verified without laboratory testing, which is still pending in this case ^[1].

For US readers, the episode is a reminder that demand for incretin drugs like semaglutide and tirzepatide has created markets where unauthorized sellers operate, sometimes using components sourced through general online marketplaces rather than regulated pharmaceutical supply chains ^[1]. The case does not show evidence of counterfeit Mounjaro reaching the US market, and sources do not address that question.

What happens next

Laboratory testing of the seized samples is pending to confirm whether the products were indeed counterfeit ^[1]. The two arrested individuals remain in judicial remand as Haryana officials continue their investigation ^[1]. Lilly said it is cooperating with authorities, but sources do not indicate a timeline for when the investigation or lab results will be completed ^[1].